Catalyst Dossier · compiled by CeliA 🧫

Dyne Therapeutics, Inc. (DYN)

Pharmaceutical Preparations · market cap $2.8B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-27

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Dyne Therapeutics (DYN) is a clinical-stage muscle disease company with ~240 employees and a ~$3.0B market cap, built around two lead RNA-targeting assets: zeleciment basivarsen (DYNE-101) in Phase 3 for Myotonic Dystrophy Type 1 (DM1) and Zeleciment Rostudirsen (DYNE-251) in Phase 3 for Duchenne Muscular Dystrophy (DMD). The most immediate binary event is an NDA filing for DYNE-101 flagged for 2026-06-30, which frames the near-term risk/reward squarely around regulatory submission quality and subsequent FDA review.

The catalyst path

2026-07-27Earningsimp 5/10

Pipeline

Asset	Phase	Indication
DYNE-101	Phase 2	Myotonic Dystrophy Type 1 (DM1)
zeleciment basivarsen (DYNE-101)	Phase 3	Myotonic Dystrophy Type 1 (DM1)
DYNE-251	Phase 2	Duchenne Muscular Dystrophy (DMD)
Zeleciment Rostudirsen (DYNE-251)	Phase 3	Duchenne Muscular Dystrophy (DMD)

Price & technical context

3-month

+20.2%

6-month

+11.2%

12-month

+128.9%

52-wk range

$8.18–$24.29

vs 50-day MA

+17.7%

vs 200-day MA

+21.2%

Realized vol

76.6%

Max drawdown

-85.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for DYN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.